Riluzole Oral Suspension

What This Riluzole Shortage Record Means

The FDA Drug Shortages database lists this record for Riluzole Oral Suspension (brand: TEGLUTIK) from EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) with a current status of Active Shortage. The affected dosage form is Oral Suspension, presented as Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1). Shortages are tracked at the manufacturer and presentation level — other manufacturers or formulations of the same generic may remain available, which is why pharmacists often can source a working substitute even when one record is flagged.

This shortage was first reported on Jan 26, 2024 and was last updated Mar 16, 2026. FDA-supplied reason codes are not recorded for this entry; common drivers include manufacturing quality issues, raw-material constraints, demand surges, and voluntary business decisions to discontinue a presentation. There are 3 other current records in this database covering the same generic, which gives a fuller picture of how disruption is playing out across manufacturers and dosage forms.

A shortage listing is a supply-side signal, not a patient-level instruction. Access can vary dramatically by pharmacy, region, hospital system, and insurance formulary — local pharmacists have real-time visibility that a national database cannot provide. Therapeutic substitutes often exist in the same class, but switching decisions belong with your prescriber, who weighs efficacy, dosing conversion, interaction profile, and personal history. This page summarizes public FDA data for educational reference only and is not medical advice. If your medication is affected, contact your pharmacist and prescriber to plan an appropriate response.